Medivir AB (STU:MVR0) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:MVR0 Medivir AB STU:MVR0
30 GF Score
Price €0.15
GF Value €0.09
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medivir AB SpecialCharges?

Special Charges only applies to banks.

STU:MVR0
30GF Score
Medivir AB STU:MVR0
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medivir AB (STU:MVR0) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of €0.15 is trading 71.3% above its estimated GF Value™ of €0.09. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for STU:MVR0:

  • SpecialCharges:
  • GF Value™: €0.09 vs. price of €0.15 (71.3% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the STU:MVR0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medivir AB Business Description

Other Exchanges MVIR:SwedenMVIRs:UK0GP7:UK
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
30GF Score

Get the complete analysis for STU:MVR0

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.09
GF Value